Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Chamberlain

Showing results (271-280 of 277) with videos related to

Pageof 28
Sort By:
You have reached the last page of results.This site can display upto 277 results.
Molecular Cancer Therapeutics|October 15, 2009
GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancersPeter Sabbatini, Susan Korenchuk, Jason L Rowand, et al.
Bioorganic & Medicinal Chemistry Letters|December 6, 2008
Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: potent inhibitors of the IGF-1R receptor tyrosine kinaseStanley D Chamberlain, Joseph W Wilson, Felix Deanda, et al.
Bioorganic & Medicinal Chemistry Letters|December 17, 2008
Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivityStanley D Chamberlain, Anikó M Redman, Joseph W Wilson, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 2005
Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580James G Conway, Brad McDonald, Janet Parham, et al.
Bioorganic & Medicinal Chemistry Letters|February 25, 2009
Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein bindingKyle A Emmitte, George M Adjabeng, George M Adjebang, et al.
Bioorganic & Medicinal Chemistry Letters|November 26, 2008
Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitorsKirk L Stevens, Krystal J Alligood, Jennifer G Badiang Alberti, et al.
JAMA Ophthalmology|December 4, 2025
Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event ReportingNeel D Pasricha, Stella K Kim, Asim V Farooq, et al.
Pageof 28

Showing results (271-280 of 277) with videos related to

Sort By:
Pageof 28
You have reached the last page of results.This site can display upto 277 results.
Molecular Cancer Therapeutics|October 15, 2009
GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancersPeter Sabbatini, Susan Korenchuk, Jason L Rowand, et al.
Bioorganic & Medicinal Chemistry Letters|December 6, 2008
Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: potent inhibitors of the IGF-1R receptor tyrosine kinaseStanley D Chamberlain, Joseph W Wilson, Felix Deanda, et al.
Bioorganic & Medicinal Chemistry Letters|December 17, 2008
Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivityStanley D Chamberlain, Anikó M Redman, Joseph W Wilson, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 2005
Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580James G Conway, Brad McDonald, Janet Parham, et al.
Bioorganic & Medicinal Chemistry Letters|February 25, 2009
Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein bindingKyle A Emmitte, George M Adjabeng, George M Adjebang, et al.
Bioorganic & Medicinal Chemistry Letters|November 26, 2008
Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitorsKirk L Stevens, Krystal J Alligood, Jennifer G Badiang Alberti, et al.
JAMA Ophthalmology|December 4, 2025
Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event ReportingNeel D Pasricha, Stella K Kim, Asim V Farooq, et al.
Pageof 28